These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 23777016)

  • 1. [Study of HIV protease dimerization (PD) and identification of novel PD inhibitors (PDIs)].
    Koh Y
    Jpn J Antibiot; 2013 Feb; 66(1):45-53. PubMed ID: 23777016
    [No Abstract]   [Full Text] [Related]  

  • 2. "Wide-open" 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target.
    Martin P; Vickrey JF; Proteasa G; Jimenez YL; Wawrzak Z; Winters MA; Merigan TC; Kovari LC
    Structure; 2005 Dec; 13(12):1887-95. PubMed ID: 16338417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 protease: structure, dynamics, and inhibition.
    Louis JM; Ishima R; Torchia DA; Weber IT
    Adv Pharmacol; 2007; 55():261-98. PubMed ID: 17586318
    [No Abstract]   [Full Text] [Related]  

  • 4. HIV protease: enzyme function and drug resistance.
    Gulnik S; Erickson JW; Xie D
    Vitam Horm; 2000; 58():213-56. PubMed ID: 10668400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative studies on inhibitors of HIV protease: a target for drug design.
    Jayaraman S; Shah K
    In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.
    Ohtaka H; Schön A; Freire E
    Biochemistry; 2003 Nov; 42(46):13659-66. PubMed ID: 14622012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward the first nonpeptidic molecular tong inhibitor of wild-type and mutated HIV-1 protease dimerization.
    Vidu A; Dufau L; Bannwarth L; Soulier JL; Sicsic S; Piarulli U; Reboud-Ravaux M; Ongeri S
    ChemMedChem; 2010 Nov; 5(11):1899-906. PubMed ID: 20936621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resolution of discordant HIV-1 protease resistance rankings using molecular dynamics simulations.
    Wright DW; Coveney PV
    J Chem Inf Model; 2011 Oct; 51(10):2636-49. PubMed ID: 21902276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into the mechanism of drug resistance: X-ray structure analysis of multi-drug resistant HIV-1 protease ritonavir complex.
    Liu Z; Yedidi RS; Wang Y; Dewdney TG; Reiter SJ; Brunzelle JS; Kovari IA; Kovari LC
    Biochem Biophys Res Commun; 2013 Feb; 431(2):232-8. PubMed ID: 23313846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural insights into the South African HIV-1 subtype C protease: impact of hinge region dynamics and flap flexibility in drug resistance.
    Naicker P; Achilonu I; Fanucchi S; Fernandes M; Ibrahim MA; Dirr HW; Soliman ME; Sayed Y
    J Biomol Struct Dyn; 2013 Dec; 31(12):1370-80. PubMed ID: 23140382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-resistance within the protease inhibitor class.
    Race E
    Antivir Ther; 2001; 6 Suppl 2():29-36. PubMed ID: 11678476
    [No Abstract]   [Full Text] [Related]  

  • 12. An alternative strategy for inhibiting multidrug-resistant mutants of the dimeric HIV-1 protease by targeting the subunit interface.
    Bannwarth L; Reboud-Ravaux M
    Biochem Soc Trans; 2007 Jun; 35(Pt 3):551-4. PubMed ID: 17511649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into the mechanism of drug resistance: X-ray structure analysis of G48V/C95F tethered HIV-1 protease dimer/saquinavir complex.
    Prashar V; Bihani SC; Das A; Rao DR; Hosur MV
    Biochem Biophys Res Commun; 2010 Jun; 396(4):1018-23. PubMed ID: 20471372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural insights into the mechanisms of drug resistance in HIV-1 protease NL4-3.
    Heaslet H; Kutilek V; Morris GM; Lin YC; Elder JH; Torbett BE; Stout CD
    J Mol Biol; 2006 Mar; 356(4):967-81. PubMed ID: 16403521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular dynamics studies on HIV-1 protease drug resistance and folding pathways.
    Cecconi F; Micheletti C; Carloni P; Maritan A
    Proteins; 2001 Jun; 43(4):365-72. PubMed ID: 11340653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural and kinetic analysis of pyrrolidine-based inhibitors of the drug-resistant Ile84Val mutant of HIV-1 protease.
    Böttcher J; Blum A; Heine A; Diederich WE; Klebe G
    J Mol Biol; 2008 Nov; 383(2):347-57. PubMed ID: 18692068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Among the devils in the details are protease sequence, susceptibility, and structure in CRF02_AG viruses.
    Katzenstein D; Ogden R
    Clin Infect Dis; 2005 Jul; 41(2):252-4. PubMed ID: 15983924
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel strategies for targeting the dimerization interface of HIV protease with cross-linked interfacial peptides.
    Bowman MJ; Chmielewski J
    Biopolymers; 2002; 66(2):126-33. PubMed ID: 12325162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance.
    de Mendoza C; Garrido C; Corral A; Zahonero N; Soriano V
    AIDS; 2008 Jan; 22(2):311-3. PubMed ID: 18097236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.